NCT05844449
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
Enrolling by Invitation
PHASE3Ages 1+InterventionalTreatmentVertex Pharmaceuticals Incorporated
~174 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:VNZ/TEZ/D-IVA
At a glance
Recruiting sites
0 of 37 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
Measured over From Baseline up to Week 100
+1 more outcome measured
Conditions
Where it's being run
37 sites across 23 statesAustralia4
Ohio3
Germany3
California2
Missouri2
Canada2
France2
Sweden2
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Meets at least 1 of the following criteria:
Completed study drug treatment in Part A
Had study drug interruption(s) in Part A, but did not permanently discontinue study drug and completed study visits up to the last scheduled visit of the treatment period of Part A
Exclusion
Hepatic cirrhosis with portal hypertension, moderate hepatic impairment, or severe hepatic impairment that might pose an additional risk in administering study drug
History of solid organ, hematological transplantation, or cancer
History of drug intolerance in the parent study
What this trial measures
- Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)From Baseline up to Week 100
- Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)From Baseline up to Week 196